Microglial immunophenotype in dementia with Alzheimer's pathology.

J Neuroinflammation

Clinical Neurosciences, Clinical and Experimental Sciences Academic Unit, Faculty of Medicine, Southampton General Hospital, University of Southampton, Southampton, SO16 6YD, UK.

Published: June 2016

Background: Genetic risk factors for Alzheimer's disease imply that inflammation plays a causal role in development of the disease. Experimental studies suggest that microglia, as the brain macrophages, have diverse functions, with their main role in health being to survey the brain parenchyma through highly motile processes.

Methods: Using the Medical Research Council Cognitive Function and Ageing Studies resources, we have immunophenotyped microglia to investigate their role in dementia with Alzheimer's pathology. Cerebral cortex obtained at post-mortem from 299 participants was analysed by immunohistochemistry for cluster of differentiation (CD)68 (phagocytosis), human leukocyte antigen (HLA)-DR (antigen-presenting function), ionized calcium-binding adaptor molecule (Iba1) (microglial motility), macrophage scavenger receptor (MSR)-A (plaque-related phagocytosis) and CD64 (immunoglobulin Fcγ receptor I).

Results: The presence of dementia was associated positively with CD68 (P < 0.001), MSR-A (P = 0.010) and CD64 (P = 0.007) and negatively with Iba1 (P < 0.001). Among participants without dementia, the cognitive function according to the Mini-Mental State Examination was associated positively with Iba1 (P < 0.001) and negatively with CD68 (P = 0.033), and in participants with dementia and Alzheimer's pathology, positively with all microglial markers except Iba1. Overall, in participants without dementia, the relationship with Alzheimer's pathology was negative or not significant, and positive in participants with dementia and Alzheimer's pathology. Apolipoprotein E (APOE) ε2 allele was associated with expression of Iba1 (P = 0.001) and MSR-A (P < 0.001) and APOE ε4 with CD68, HLA-DR and CD64 (P < 0.001).

Conclusions: Our findings raise the possibility that in dementia with Alzheimer's pathology, microglia lose motility (Iba-1) necessary to support neurons. Conversely, other microglial proteins (CD68, MSR-A), the role of which is clearance of damaged cellular material, are positively associated with Alzheimer's pathology and impaired cognitive function. In addition, our data imply that microglia may respond differently to Aβ and tau in participants with and without dementia so that the microglial activity could potentially influence the likelihood of developing dementia, as supported by genetic studies, highlighting the complexity and diversity of microglial responses.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4890505PMC
http://dx.doi.org/10.1186/s12974-016-0601-zDOI Listing

Publication Analysis

Top Keywords

dementia alzheimer's
8
alzheimer's pathology
8
microglial immunophenotype
4
immunophenotype dementia
4
pathology background
4
background genetic
4
genetic risk
4
risk factors
4
factors alzheimer's
4
alzheimer's disease
4

Similar Publications

Alzheimer's disease (AD) is the most frequent cause of dementia. Since there are complex pathophysiological mechanisms behind AD, and there is no effective treatment strategy, it is necessary to introduce novel multi-targeting agents with fewer side effects and higher efficacy. Polydatin (PD) is a naturally occurring resveratrol glucoside employing multiple mechanisms toward neuroprotection.

View Article and Find Full Text PDF

Background: ApoE polymorphism especially APOE ε4 play a central role in AD pathophysiology through Aβ-dependent and Aβ-independent neuropathogenic pathway in the Alzheimer's disease.

Method: A cross-sectional study was performed on non diseased and diseased subjects with stroke from outpatient services of Neurology department of Institute of Human Behavior & Allied Sciences (IHBAS), New Delhi (India). Subjects diagnosed with various dementias including Alzheimer's disease, non AD dementias and dementia with Behavior & Psychological symptoms were taken.

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.

Background: Drugs targeting Alzheimer's disease (AD) pathology are likely to be most effective in the presymptomatic stage, where individuals harbor AD pathology but have not manifested symptoms. Neuroimaging approaches can help to identify such individuals, but are costly for population-wide screening. Cost-effective screening is needed to identify those who may benefit from neuroimaging, such as those at risk of developing clinical disease.

View Article and Find Full Text PDF

Background: biomarkers are essential in order to make a diagnosis with a high level of accuracy in patients with cognitive and behavior complaints. However, molecular imaging biomarkers not always provide an answer in daily clinical practice.

Methods: retrospective and descriptive study in patients with Amyloid PET (APscans) implemented according to rational use of this technic, between January 2019-November 2023 in Neurology Department, Infanta Leonor Hospital, Madrid, Spain.

View Article and Find Full Text PDF

Background: The ARTS biomarker is a fully automated software container that predicts the presence of arteriolosclerosis based on in-vivo MRI data and demographic features. The present study describes findings from the instrumental and clinical validation of ARTS conducted by the MarkVCID consortium.

Method: Instrumental validation of ARTS involved assessment of inter-rater reliability, test-retest repeatability, and inter-scanner reproducibility.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!